NCT00006071 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Gryglewski RJ, Botting RM, Vane JR
Mediators produced by the endothelial cell. Hypertension. 1988 Dec;12(6):530-48. Review.
Kiowski W, Lüscher TF, Linder L, Bühler FR
Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991 Feb;83(2):469-75.
Vane JR, Anggård EE, Botting RM
Regulatory functions of the vascular endothelium. N Engl J Med. 1990 Jul 5;323(1):27-36. Review.

Effects of Rosiglitazone on Endothelium-Dependent Vasodilation and on Endothelin Activity in Patients With Essential Hypertension and in Patients With Hypercholesterolemia

Details for clinical trial NCT00006071

Clinical trial NCT00006071 - References